ReShape Lifesciences Inc.

Missed our patent news? ReShape was recently granted a key international patent from the State of Israel Patent Office for its Diabetes Neuromodulation technology. Patent entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control Systems and Methods,” will provide protection until December 4, 2039. The Diabetes Neuromodulation system utilizes its proprietary vagus nerve block (vBloc™) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity. Granting of this key international patent is a testament to this innovative technology, which has demonstrated the ability to reduce the reliance on medications for diabetics in a personalized manner, aiming to lower treatment costs and complications associated with poorly controlled blood glucose and medication non-compliance Read the details: https://lnkd.in/gnXYZF_X #Tech #HealthTech #MedTech #WeightLoss #Diabetes #MedicalTechnology #Innovation #Healthcare

ReShape received a Notice of Allowance from the USPTO for patent application “High-Frequency Low Duty Cycle Patterns for Neural Regulation.”    The Diabetes Neuromodulation system leverages its proprietary vagus nerve block (vBloc™) technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity.   ICYMI, read more https://lnkd.in/gHdPNBgU #diabetes #medtech #innovation

In case you missed it: ReShape Lifesciences® (Nasdaq: RSLS) has signed an agreement with Liaison Medical for distribution of ReShape’s next generation, enhanced ReShape Lap-Band® 2.0 FLEX  in Canada. Following Health Canada's approval in November 2024, this partnership with one of Canada's largest surgical device distributors marks a major step in expanding access to our innovative weight loss solutions. The ReShape Lap-Band® 2.0 FLEX, with its advanced FLEX technology, is designed to enhance patient comfort and potentially reduce the need for in-office adjustments. We anticipate, over time, this will meaningfully add to the sales of the Lap-Band® franchise. Learn more about this development: https://lnkd.in/gHQpAq3t #MedTech #Canada #BariatricSurgery #MarketExpansion #WeightLoss #Healthcare

ReShape Lifesciences® (Nasdaq: RSLS) Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology. Vagal neuromodulation offers a novel approach to treating type 2 diabetes and hypoglycemia. Read the press release here: https://lnkd.in/garvBGky #MedicalTechnology #Diabetes #Neuromodulation #VagusNerve

ReShape Lifesciences® (Nasdaq: RSLS) Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation ReShape Lap-Band® 2.0 FLEX. Liaison Medical is among the largest surgical device distributors in Canada. CEO Paul F. Hickey comments: “The signing of this distribution agreement in Canada, on the heels of the November 2024 approval by Health Canada for the ReShape Lap-Band® 2.0 FLEX, is a testament to our commitment to broadly launching this important product to improve the patient experience. Initial surgeon feedback from our limited market release of the ReShape Lap-Band® 2.0 FLEX in the U.S. was overwhelmingly positive. We look forward to working closely with @LiaisonMedical on the launch of the ReShape Lap-Band 2.0 FLEX in Canada, which we believe, over time, will meaningfully add to the sales of the Lap-Band franchise.” Read the press release: https://lnkd.in/gHQpAq3t #MedTech #LapBand #WeightLossSurgery #MedicalDistribution #Canada

Jon Waataja, PhD, Director of Research at ReShape Lifesciences comments on new U.S. patent, “Type 2 diabetes is a worldwide issue and continues to be difficult to treat effectively, despite the availability of medication, surgery, and dietary interventions. ReShape’s Diabetes Neuromodulation technology regulates blood glucose by selectively modulating vagal block and stimulation to the liver and pancreas. Studies have shown improved glycemic control in both a Zucker rat model of Type 2 Diabetes Mellitus (T2DM) and an alloxan-treated swine model of T2DM. To date, our team has successfully completed the pre-clinical development of the device, employing bioelectronics to optimize insulin production and manage blood glucose levels in a personalized manner, with the potential to treat Type 2 diabetes and hypoglycemia.” Dive into the announcement here: https://lnkd.in/gDKp4j2q #MedTech #MedicalTechnology #Diabetes #Neuromodulation #VagusNerve

ReShape Lifesciences® (Nasdaq: RSLS) Partners with Motion Informatics Ltd to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market. “The signing of this agreement with Motion Informatics marks a significant milestone for ReShape as we expand and diversify into rehabilitation technology. This partnership presents a unique opportunity to bring cutting-edge, neurorehabilitation solutions to the U.S. market. We are particularly excited to distribute the FDA cleared and commercially available Stimel-03, a breakthrough system that integrates Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time electromyographic (EMG) biofeedback into a single, patient-responsive platform—redefining rehabilitation for patients recovering from stroke, injury, or surgery. Motion Informatics’ innovative devices align well with our commitment to improving patient outcomes, complementing our core competencies including commercialization of differentiated products including our Lap-Band® 2.0 FLEX, designed to improve patients’ quality of life while driving meaningful clinical and commercial impact.” Read the press release here: https://lnkd.in/gQxZnh-9 #Neurorehabilitation #NeuroTech #AI #MedTech

CEO Paul F. Hickey comments, “Allowance for this newest patent, on the heels of the recently announced Israeli patent, serves as strong evidence of the promise of this groundbreaking technology, which has shown the potential to reduce dependence on medications for diabetics through a personalized approach. By optimizing glucose control, the technology aims to lower treatment costs and minimize complications related to poorly managed blood sugar and medication non-compliance. Like other patent families within ReShape, the Diabetes Neuromodulation technology is supported by a robust intellectual property portfolio, comprising 62 issued or pending patents. These cover vagal neuromodulation, glucose control, AI, and Bluetooth applications, ensuring a clear path to commercialization while providing strong protection against competitive threats.” In case you missed it, read the announcement: https://lnkd.in/gDKp4j2q #MedTech #MedicalTechnology #Diabetes #Neuromodulation #VagusNerve

ReShape Lifesciences® (Nasdaq: RSLS) Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update. Read the press release here: https://lnkd.in/gXRufN8K

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology. Vagal neuromodulation provides route to treat type 2 diabetes and hypoglycemia. Read the press release here: https://lnkd.in/gDKp4j2q #MedTech #MedicalTechnology #Diabetes #Neuromodulation #VagusNerve